Press Releases Belite Bio, Inc

Equities

BLTE

US07782B1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
48.55 ^USD	-0.92%		-1.32%	+6.12%

Jun. 12	Belite Bio Obtains Pioneer Drug Designation for Stargardt Disease Treatment in Japan	MT
Jun. 12	Belite Bio, Inc. Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Belite Bio to Present at the JonesHealthcare Seaside Summit	Jul. 08	GL
Belite Bio to Present at the JonesHealthcare Seaside Summit	Jul. 08	AQ
Belite Bio Receives Sakigake Designation of Tinlarebant for Stargardt Disease in Japan	Jun. 13	AQ
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan	Jun. 12	GL
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference	May. 14	GL
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference	May. 14	AQ
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update	May. 13	GL
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	May. 13	GL
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	May. 13	AQ
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results	May. 08	GL
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant	May. 06	GL
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting	May. 06	GL
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting	May. 01	GL
Belite Bio Announces $25 Million Registered Direct Offering	Apr. 25	GL
Belite Bio : Initiates Stargardt Disease Clinical Trial in Japan	Apr. 22	PU
Belite Bio : Announces MHRA Submission of Tinlarebant for Stargardt Disease Clinical Trial in the United Kingdom	Apr. 18	PU
Belite Bio : Submits US IND Amendment to Initiate a Phase 2/3 Clinical Trial of Tinlarebant in Stargardt Disease	Mar. 25	PU
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	Mar. 22	GL
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website	Mar. 11	GL
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Mar. 11	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Belite Bio, Inc

Equities

BLTE

US07782B1044

Press Releases

Filters